Risk-stratified therapy with osteoanabolic agents improves outcomes

Patients with a very high or imminent fracture risk should be considered for (first-line) therapy with ostoanabolic substances. Both patient selection and planning of therapy sequences are decisive factors for the success of treatment. Prof. Dr. med. Christian Meier, Head Physician Endocrinology and Osteology, University Hospital Basel, gave an up-to-date overview.